Navigation Links
No on Prop. 37: French Rat Study Author Made Reporters Sign Confidentiality Agreements Prohibiting them from Consulting Independent Scientific Experts
Date:9/21/2012

SACRAMENTO, Calif., Sept. 21, 2012 /PRNewswire/ -- According to new reports in the New York Times, BBC, Reuters and other publications, the authors of the highly controversial French study of rats and biotech foods forced reporters to sign non-disclosure agreements prohibiting journalists from validating the report's findings with independent scientists. Clearly, its authors were concerned that the now-debunked study would wilt under scientific scrutiny, which is exactly what has happened now that the report has been reviewed by independent scientific experts.

According to the BBC:

"In a move regarded as unusual by the media, the French research group refused to provide copies of the journal paper to reporters in advance of its publication, unless they signed non-disclosure agreements. The NDAs would have prevented the journalists from approaching third-party researchers for comment."

The New York Time's Dot Earth blog was even more blunt:

"I have to place it in a big bin of suspect studies "done by people out to prove something rather than investigate something," as the evolutionary biologist Michael Eisen said in a late update to my previous post on this work."

The Yes on Prop 37 campaign was coordinating with the French authors from the very beginning. In fact, within a few hours of the study release, Yes on 37 issued a media advisory announcing a press conference with the study's authors.

"It is clear that this so-called study is nothing more than a propaganda piece intended to create false fear and misinformation to help support the flawed Prop 37 campaign," said No on 37 campaign spokesperson Kathy Fairbanks. "After just a few hours of scrutiny, respected scientists and medical reviewers thoroughly discredited the study, its methodology and the authors.  Yes on 37 can't sell their flawed measure based on the facts, so they're forced to result to cheap tricks and junk science."

Paid for by No on 37: Coalition Against the Deceptive Food Labeling Scheme, sponsored by Farmers, Food Producers, and Grocers.  Major funding by Monsanto Company, E.I. DuPont de Nemours & Co., Grocery Manufacturers Association (GMA) and more than 40 food company members.  For a full list of donors visit www.NoProp37.com/donors. - 1-800-331-0850 - www.NoProp37.com

About Prop. 37
Proposition 37 would ban the sale of tens of thousands of perfectly-safe, common grocery products only in California unless they are specially repackaged, relabeled or remade with higher cost ingredients. Prop 37 is a deceptive, deeply flawed food labeling scheme that would add more government bureaucracy and taxpayer costs, create new frivolous lawsuits, and increase food costs by billions — without providing any health or safety benefits. That's why Prop 37 is opposed by a broad coalition of family farmers, scientists, doctors, business, labor, taxpayers and consumers.


'/>"/>
SOURCE No on Prop. 37
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. JPM-TMT Awards New Contract to Study Administration using Marburg Virus Drug
4. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
5. Science study shows promiscuous enzymes still prevalent in metabolism
6. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
9. SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
10. Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
11. Sosei Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... York, New York (PRWEB) , ... ... ... Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined the Human ... and immunotherapies for infectious diseases and cancer. , The Human Vaccines ...
(Date:2/10/2016)... Feb. 10, 2016  Matchbook, Inc., a company ... growing biotech companies, announced today the appointment of ... Advisor. Jim brings nearly 25 years of experience ... having spent nearly two decades in executive level ... Procurement at Genzyme and, most recently headed global ...
(Date:2/10/2016)... , ... February 10, 2016 , ... LATHAM, NEW YORK... ... the SPIE Photonics West conference in San Francisco’s Moscone Center from February ... the same venue. , These latest InGaAs PIN diode standard packages feature a ...
(Date:2/10/2016)... Boston, MA (PRWEB) , ... February 10, 2016 ... ... system is now available on Microsoft Azure. On Azure, Arvados provides capabilities for ... “We saw clear demand for Microsoft Azure from major institutions collecting and analyzing ...
Breaking Biology Technology:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
Breaking Biology News(10 mins):